Literature DB >> 33395681

Tanshinone IIA Ameliorates Inflammation Response in Osteoarthritis via Inhibition of miR-155/FOXO3 Axis.

Biao Zhou1,2, Lin-Hui Li1, Li-Ming Tan3,4, Wen-Bing Luo5,6, Hui Xiong6, Xiao-Long Lu7, Dan Liu8, Wang-Yang Li6, Yu-Xing Guo6, Zhi Tang6, Li-Guo Zhu9.   

Abstract

BACKGROUND: Osteoarthritis (OA) is the most common joint disorder characterized by degeneration of the articular cartilage and joint destruction with an associated risk of mobility disability in elderly people. Although a lot of achievements have been made, OA is still regarded as an incurable disease. Therefore, the pathological mechanisms and novel therapeutic strategies of OA need more investigation.
METHODS: MTT assay was conducted to measure the viability of chondrocytes after LPS treatment. Cell apoptosis was analyzed by annexin V/propidium iodide labeling. ELISA was used to determine the concentrations of interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α in the culture supernatant of chondrocytes. The expression level of miR-155, IL-1β, FOXO3, TNF-α, IL-6, caspase-3, and caspase-9 in chondrocytes was analyzed by RT-qPCR or Western blot.
RESULTS: We found that LPS led to inflammatory responses, cell apoptosis, and increased miR-155 expression in human articular chondrocytes. Tanshinone IIA could inhibit LPS-induced inflammation and cell apoptosis of chondrocytes via regulating the expression of miR-155 and FOXO3. miR-155 directly targeted the 3'-UTR of FOXO3 to regulate its expression.
CONCLUSIONS: Taken together, our data suggest tanshinone IIA ameliorates inflammation response in OA via inhibition of the miR-155/FOXO3 axis, and provide some evidences that tanshinone IIA could be designed and developed as a new promising clinical therapeutic drug for OA patients.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  FOXO3; Inflammation; Osteoarthritis; Tanshinone IIA; miR-155

Year:  2021        PMID: 33395681     DOI: 10.1159/000505493

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  2 in total

1.  Methylation Mediated Silencing of miR-155 Suppresses the Development of Preeclampsia In Vitro and In Vivo by Targeting FOXO3.

Authors:  Xiaohua Luo; Ci Pan; Xiaopei Guo; Cunhua Gu; Yulian Huang; Jing Guo; Ying Zeng; Jinjing Yue; Shihong Cui
Journal:  Mediators Inflamm       Date:  2022-05-26       Impact factor: 4.529

2.  miR-155 inhibits chondrocyte pyroptosis in knee osteoarthritis by targeting SMAD2 and inhibiting the NLRP3/Caspase-1 pathway.

Authors:  Gen Li; Lijun Xiu; Xiaoyun Li; Lisha Ma; Jihui Zhou
Journal:  J Orthop Surg Res       Date:  2022-01-28       Impact factor: 2.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.